NCT00784784View on ClinicalTrials.gov

Zanamivir Versus Trivalent Split Virus Influenza Vaccine

PHASE3CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

May 31, 2009

Study Completion Date

June 30, 2009

Conditions
Influenza
Interventions
BIOLOGICAL

Fluviral

One dose

DRUG

Zanamivir

10 mg, OD, for duration of influenza season (10-23 weeks)

Trial Locations (1)

M5G 1X5

Mount Sinai Hospital, Toronto

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Mount Sinai Hospital, Canada

OTHER

NCT00784784 - Zanamivir Versus Trivalent Split Virus Influenza Vaccine | Biotech Hunter | Biotech Hunter